Fujifilm hopeful of doubling growth for its medical systems business in India

IMT News Desk
IMT News Desk
· 2 min read

With steady eye on Indian healthcare market, the Indian arm of the Japanese imaging company Fujifilm India Private Limited is set to double its medical system business.  “We are growing at 15 to 20 per cent in the (medical systems) segment. My hope is that we would grow more than double in the next five years,” Fujifilm India Managing Director Yasunobu Nishiyama told PTI.

According to PTI, medical system products account for about 50 per cent of the company’s Rs 1,000 crore turnover in India, accounting for about 2 per cent of its global business.

“We want to promote better medical equipment systems in tier II and III cities. The world is going digital and in India too, analogue machines are being changed to digital X- ray,” he told PTI. “Now the demand is very huge, specially in PPP and private hospitals. So we are collaborating with them,” he added.

In Feb, 2017 Fujifilm signed a contract with Pune based KRSNAA diagnostics Pvt Ltd to convert 1000 X-Ray setups from analog to digital across India. The contract comes as a part of tender won by KRSNAA Diagnostics Pvt Ltd from Government of Assam to install Computer Radiography machines and Imagers. As part of the contract, FujiFilm will supply and install 1000 units of FCR Prima and 1200 units of DRYPIX imager.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk